Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis

This study has been completed.
Astellas Pharma China, Inc.
Information provided by (Responsible Party):
Astellas Pharma Inc Identifier:
First received: March 16, 2011
Last updated: March 8, 2016
Last verified: March 2016
To evaluate the efficacy and safety of tacrolimus capsules in patients with myasthenia gravis who are inadequately treated by glucocorticoid.

Condition Intervention Phase
Myasthenia Gravis
Drug: Tacrolimus capsule
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blinded, Placebo-controlled, and Multi-centered Clinical Trial Evaluating the Efficacy and Safety of Tacrolimus Capsule in Myasthenia Gravis That Was Insufficiently Treated by Glucocorticoid Therapy

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Change from baseline in quantitative myasthenia gravis (QMG) score for disease severity [ Time Frame: Baseline and at 24 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in QMG score for disease severity [ Time Frame: Baseline and at 4 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in QMG score for disease severity [ Time Frame: Baseline and at 8 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in QMG score for disease severity [ Time Frame: Baseline and at 12 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in QMG score for disease severity [ Time Frame: Baseline and at 16 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in QMG score for disease severity [ Time Frame: Baseline and at 20 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Changes in Osserman classification [ Time Frame: Baseline and at 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks and 24 weeks ] [ Designated as safety issue: No ]
  • Changes in myasthenia gravis activity of daily living scale [ Time Frame: Baseline and at 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks and 24 weeks ] [ Designated as safety issue: No ]

Enrollment: 83
Study Start Date: March 2011
Study Completion Date: May 2014
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: tacrolimus group Drug: Tacrolimus capsule
Other Names:
  • Prograf
  • FK506
Placebo Comparator: placebo group Drug: Placebo


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • diagnosed as myasthenia gravis (MG) by clinical diagnosis
  • QMG scores ≥7 at the time of enrollment
  • basic treatment drugs are mainly glucocorticoids, and the efficacy of glucocorticoid therapy was not sufficient

Exclusion Criteria:

  • receiving blood purification therapy or immunoglobulin therapy within 8 weeks before the study
  • QMG swallowing function score ≥ 2 points or QMG vital capacity = 3
  • abnormal hepatic functions
  • uncontrolled diabetes patients
  • hyperkalemia patients
  • immuno-inhibitors are forbidden due to malignancy, history of malignancy or history of HIV infection
  • patients who are allergic to Tacrolimus or macrolide antibiotics
  • receiving other immuno-inhibitors within 12 weeks
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01325571

Beijing, China
Guangdong, China
Jiangsu, China
Jilin, China
Shandong, China
Shanghai, China
Sichuan, China
Wuhan, China
Zhejiang, China
Sponsors and Collaborators
Astellas Pharma Inc
Astellas Pharma China, Inc.
Study Chair: Use Central Contact Astellas Pharma Inc
  More Information

Additional Information:
Responsible Party: Astellas Pharma Inc Identifier: NCT01325571     History of Changes
Other Study ID Numbers: F506-CL-0611 
Study First Received: March 16, 2011
Last Updated: March 8, 2016
Health Authority: China: Food and Drug Administration
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by Astellas Pharma Inc:

Additional relevant MeSH terms:
Myasthenia Gravis
Muscle Weakness
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Pathologic Processes
Signs and Symptoms
Autoimmune Diseases of the Nervous System
Neuromuscular Junction Diseases
Neuromuscular Diseases
Autoimmune Diseases
Immune System Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on January 14, 2017